X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20428) 20428
Book Review (3488) 3488
Publication (2668) 2668
Book Chapter (93) 93
Conference Proceeding (38) 38
Dissertation (29) 29
Magazine Article (4) 4
Book / eBook (3) 3
Government Document (3) 3
Paper (2) 2
Streaming Video (2) 2
Web Resource (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17116) 17116
humans (13714) 13714
animals (6701) 6701
apoptosis (6494) 6494
cancer (6399) 6399
cell line, tumor (6118) 6118
oncology (5909) 5909
cell biology (5466) 5466
cell cycle (5410) 5410
biochemistry & molecular biology (4018) 4018
apoptosis - drug effects (4000) 4000
mice (3656) 3656
proteins (3451) 3451
phosphorylation (3377) 3377
female (3301) 3301
cell cycle checkpoints - drug effects (3273) 3273
dna damage (3214) 3214
cell proliferation - drug effects (3150) 3150
expression (2810) 2810
immunotherapy (2533) 2533
research (2477) 2477
antineoplastic agents - pharmacology (2473) 2473
tumors (2400) 2400
analysis (2242) 2242
cell cycle proteins - metabolism (2187) 2187
activation (2173) 2173
signal transduction (2166) 2166
checkpoint (2161) 2161
kinases (2151) 2151
cell proliferation (2135) 2135
article (2134) 2134
male (2096) 2096
gene expression (2021) 2021
chemotherapy (1868) 1868
inhibition (1861) 1861
mitosis (1837) 1837
genetic aspects (1641) 1641
protein-serine-threonine kinases - metabolism (1633) 1633
care and treatment (1629) 1629
immune checkpoint (1587) 1587
p53 (1563) 1563
mutation (1555) 1555
dna (1543) 1543
dna repair (1531) 1531
cells (1513) 1513
biology (1504) 1504
multidisciplinary sciences (1503) 1503
health aspects (1484) 1484
genetics & heredity (1474) 1474
signal transduction - drug effects (1463) 1463
pharmacology & pharmacy (1445) 1445
metastasis (1440) 1440
cell survival - drug effects (1428) 1428
dna-damage (1402) 1402
cancer therapies (1382) 1382
cell cycle checkpoints (1377) 1377
research article (1375) 1375
proliferation (1365) 1365
growth (1359) 1359
tumor suppressor protein p53 - metabolism (1329) 1329
deoxyribonucleic acid--dna (1298) 1298
cytotoxicity (1285) 1285
cell cycle proteins - genetics (1281) 1281
hela cells (1272) 1272
rna interference (1259) 1259
melanoma (1225) 1225
cell line (1218) 1218
flow cytometry (1210) 1210
physiological aspects (1173) 1173
immunology (1169) 1169
cell death (1152) 1152
cell growth (1150) 1150
breast cancer (1147) 1147
protein (1144) 1144
medicine (1130) 1130
in-vitro (1113) 1113
dose-response relationship, drug (1105) 1105
mice, nude (1091) 1091
protein kinases - metabolism (1085) 1085
gene expression regulation, neoplastic (1083) 1083
xenograft model antitumor assays (1078) 1078
checkpoint kinase 1 (1070) 1070
cell division (1034) 1034
therapy (1019) 1019
saccharomyces-cerevisiae (1017) 1017
lymphocytes (982) 982
cell-cycle (981) 981
dna replication (966) 966
pathway (948) 948
medicine, research & experimental (935) 935
lung cancer (934) 934
development and progression (930) 930
down-regulation (930) 930
genes (930) 930
cell cycle checkpoints - genetics (919) 919
g2 phase cell cycle checkpoints - drug effects (905) 905
science (902) 902
protein-serine-threonine kinases - genetics (881) 881
in-vivo (877) 877
protein binding (864) 864
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (20364) 20364
German (59) 59
Chinese (28) 28
French (19) 19
Japanese (10) 10
Russian (6) 6
Korean (3) 3
Polish (3) 3
Czech (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Death and Disease, ISSN 2041-4889, 02/2012, Volume 3, Issue 2, pp. e271 - e271
Glioblastoma multiforme (GBM) are resistant to TNF alpha-induced apoptosis and blockade of TNF alpha-induced NF-kappa B activation sensitizes glioma cells to... 
NF-κB | TNFα | Casein kinase-2 | Glioblastoma | p53 | GLIOMA-CELLS | CANCER-CELLS | CARCINOMA-CELLS | TNF alpha | PROTEIN-KINASE | DOWN-REGULATION | CK2 | CELL BIOLOGY | BREAST-CANCER | glioblastoma | NF-kappa B | GROWTH ARREST | NF-KAPPA-B | casein kinase-2 | RNA, Small Interfering - genetics | Protein Binding - genetics | Proto-Oncogene Proteins c-mdm2 - genetics | Apigenin - therapeutic use | Humans | Brain Neoplasms - pathology | Gene Expression Regulation, Neoplastic | NF-kappa B - metabolism | Casein Kinase II - genetics | Dichlororibofuranosylbenzimidazole - pharmacology | Sirtuin 1 - genetics | Brain Neoplasms - metabolism | Tumor Suppressor Protein p53 - genetics | Brain - metabolism | Telomerase - genetics | Transfection | Glioblastoma - genetics | Glioblastoma - metabolism | Telomerase - metabolism | Proto-Oncogene Proteins c-mdm2 - metabolism | Signal Transduction | Casein Kinase II - antagonists & inhibitors | Tumor Suppressor Protein p53 - metabolism | Brain Neoplasms - genetics | Sirtuin 1 - antagonists & inhibitors | Brain - drug effects | Tumor Necrosis Factor-alpha - pharmacology | NF-kappa B - genetics | Cell Cycle Checkpoints - drug effects | Dichlororibofuranosylbenzimidazole - therapeutic use | Glioblastoma - pathology | Brain - pathology | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apigenin - pharmacology | Apoptosis | Index Medicus | Original
Journal Article
Nature, ISSN 0028-0836, 08/2017, Volume 548, Issue 7668, pp. 471 - 475
Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are required for the initiation and progression of various... 
BREAST-CANCER | CELLS | METHYLATION | MULTIDISCIPLINARY SCIENCES | SENESCENCE | EXPRESSION | REQUIREMENT | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Viruses - genetics | Breast Neoplasms - immunology | Humans | Transcriptome | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Regulatory - cytology | Female | Biological Mimicry - drug effects | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Disease Models, Animal | Viruses - drug effects | Viruses - immunology | Antigen Presentation - immunology | Breast Neoplasms - drug therapy | T-Lymphocytes, Regulatory - drug effects | Animals | Breast Neoplasms - genetics | Repressor Proteins - biosynthesis | Signal Transduction - drug effects | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Protein Kinase Inhibitors - therapeutic use | RNA, Double-Stranded - genetics | Cell Line, Tumor | Interferons - metabolism | Antigen Presentation - drug effects | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Oncology, Experimental | Cancer cells | Physiological aspects | Research | Protein kinases | Immunity | Cyclins | Cancer | Cell proliferation | Flow cytometry | Animal models | Phosphorylation | Senescence | Peptides | Genomics | Immune clearance | Cytotoxicity | Lymphocytes T | Genomes | Kinases | Cancer therapies | Cyclin-dependent kinase 4 | E2F protein | Breast carcinoma | Cell growth | Lymphocytes | New combinations | Cell cycle | Inhibition | Deoxyribonucleic acid--DNA | Antigen presentation | Medical research | Immune response | Immunoregulation | Intracellular levels | Double-stranded RNA | Breast cancer | Pharmacology | Gene expression | Ribonucleic acid--RNA | Immune systems | Inhibitors | Immune checkpoint | Immunogenicity | Breast | DNA methyltransferase | Interferon | Retinoblastoma | Tumors | Apoptosis | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2014, Volume 20, Issue 4, pp. 912 - 925
Journal Article
Cell Cycle, ISSN 1538-4101, 07/2012, Volume 11, Issue 13, pp. 2507 - 2517
Targeting Chk1 protein kinase can enhance the antitumor effects of radio- and chemotherapy. Recent evidence disclosed a role of Chk1 in unperturbed cell... 
targeted therapy | WEE1 | Chk1 | in vivo antitumor activity | synthetic lethality | Proteins | Binding | Landes | Calcium | Biology | Bioscience | Cell | Cycle | Organogenesis | Cancer | In vivo antitumor activity | Wee1 | Synthetic lethality | Targeted therapy | CHECKPOINT KINASE 1 | PHOSPHORYLATION | PROTEIN-KINASE | DNA-DAMAGE | G CHECKPOINT | CANCER-THERAPY | CELL BIOLOGY | GENOME INTEGRITY | CELL-CYCLE | ATR | Protein Kinases - metabolism | Protein Kinases - genetics | Pyrazoles - therapeutic use | Apoptosis - drug effects | DNA Replication - drug effects | Protein-Tyrosine Kinases - metabolism | Humans | Protein Kinases - chemistry | Transplantation, Heterologous | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - genetics | RNA Interference | Cell Cycle Proteins - genetics | Female | Drug Therapy, Combination | Nuclear Proteins - genetics | Ovarian Neoplasms - drug therapy | Pyrazoles - pharmacology | Benzodiazepinones - pharmacology | Cell Cycle Proteins - metabolism | Nuclear Proteins - metabolism | Pyrimidines - pharmacology | Drug Synergism | Animals | Mitosis - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Benzodiazepinones - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | RNA, Small Interfering - metabolism | Index Medicus
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2607 - 2619
Checkpoint inhibitors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alterations and a T-cell-inflamed phenotype. One... 
HEAD | RESPONSES | ONCOLOGY | IMMUNE SUPPRESSION | REGULATORY T-CELLS | PI3K-GAMMA | BLOCKADE | EXPRESSION | CARCINOMA | NECK-CANCER | TUMOR MICROENVIRONMENT | Neoplasms - metabolism | Immunomodulation - drug effects | Myeloid-Derived Suppressor Cells - drug effects | Lymphocyte Activation - immunology | Isoquinolines - pharmacology | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Epitopes, T-Lymphocyte - immunology | Myeloid-Derived Suppressor Cells - metabolism | Disease Models, Animal | Myeloid-Derived Suppressor Cells - immunology | Purines - pharmacology | Antibodies, Monoclonal - pharmacology | Lymphocytes, Tumor-Infiltrating - drug effects | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Neoplasms - drug therapy | Tumor Microenvironment - immunology | Animals | B7-H1 Antigen - antagonists & inhibitors | Lymphocyte Activation - drug effects | Neoplasms - immunology | Survival Analysis | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Neoplasms - pathology | Lymphocytes, Tumor-Infiltrating - immunology | Cell culture | Myeloid cells | Effectiveness | Cell survival | CD8 antigen | Effector cells | Lymphocytes T | Inflammation | Suppressor cells | Recruitment | Immune systems | Immunosuppression | Inhibitors | Immune checkpoint | Lymphocytes | PD-L1 protein | Isoforms | Head and neck | Neck | Head & neck cancer | Inhibition | Cancer | Index Medicus | immunosuppression | MDSC | IPI-145 | PI3K | head and neck cancer
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2013, Volume 132, Issue 3, pp. E149 - E157
Inhibition of centromere‐associated protein‐E (CENP‐E) has demonstrated preclinical anti‐tumor activity in a number of tumor types including neuroblastoma. A... 
CENP‐E | neuroblastoma | MEK | Ras | GSK923295 | ERK | CENP-E | MAP KINASE | RECEPTOR | ONCOLOGY | PATHWAY | THERAPEUTIC-EFFICACY | ALK KINASE | MUTATIONS | MITOTIC CHECKPOINT | SIGNAL-REGULATED KINASE | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Humans | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Drug Resistance, Neoplasm | Biomarkers, Tumor | Chromosomal Proteins, Non-Histone - antagonists & inhibitors | Pancreatic Neoplasms - drug therapy | RNA Interference | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Sarcosine - analogs & derivatives | Neuroblastoma - pathology | Sarcosine - pharmacology | Camptothecin - analogs & derivatives | Lung Neoplasms - genetics | M Phase Cell Cycle Checkpoints - drug effects | Mitogen-Activated Protein Kinase 3 - genetics | Pancreatic Neoplasms - genetics | Drug Synergism | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinase 3 - metabolism | Neuroblastoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Neuroblastoma - metabolism | RNA, Small Interfering | Camptothecin - pharmacology | Drug Screening Assays, Antitumor | Prevention | Colon cancer | Lung cancer | Oncology, Experimental | Genes | Research | Drug therapy, Combination | Protein kinases | Cancer | Proteins | Chemotherapy | Kinases | Index Medicus | Apoptosis
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, pp. e71115 - e71115
Renal cell carcinoma (RCC) is the sixth most common cancer in the US. While RCC is highly metastatic, there are few therapeutics options available for patients... 
ACTIVATED-RECEPTOR-ALPHA | THERAPY | METABOLISM | MECHANISM | MULTIDISCIPLINARY SCIENCES | C-MYC | IDENTIFICATION | PEROXISOME PROLIFERATORS | CARCINOMA | EPIDEMIOLOGY | PROGRESSION | Immunohistochemistry | Tyrosine - pharmacology | Cyclin D1 - metabolism | Kidney Neoplasms - genetics | Apoptosis - drug effects | Humans | Carcinoma, Renal Cell - genetics | Cell Survival - genetics | Apoptosis - genetics | Immunoblotting | Kidney Neoplasms - metabolism | G1 Phase - drug effects | Glycolysis - drug effects | Tyrosine - analogs & derivatives | Glycolysis - genetics | Glycolysis - physiology | RNA Interference | Deoxyglucose - pharmacology | Cell Cycle Checkpoints - genetics | G1 Phase - genetics | Cell Survival - physiology | Cell Line | Cell Survival - drug effects | PPAR alpha - antagonists & inhibitors | Carcinoma, Renal Cell - pathology | Cell Cycle Checkpoints - physiology | PPAR alpha - genetics | Glucose - pharmacology | Cyclin-Dependent Kinase 4 - metabolism | G1 Phase - physiology | Proto-Oncogene Proteins c-myc - metabolism | Carcinoma, Renal Cell - metabolism | Resting Phase, Cell Cycle - genetics | Cell Cycle Checkpoints - drug effects | Resting Phase, Cell Cycle - physiology | Cell Line, Tumor | Glucose - metabolism | Kidney Neoplasms - pathology | Resting Phase, Cell Cycle - drug effects | Oxazoles - pharmacology | Apoptosis - physiology | PPAR alpha - metabolism | Metabolomics | Energy metabolism | Nephrology | Syngeneic grafts | Toxicity | c-Myc protein | Cytotoxicity | Myc protein | Cyclin D1 | Cancer therapies | Cyclin-dependent kinase 4 | Metastases | Proteins | Allografts | Cell cycle | Xenografts | Oxidation | Inhibition | Internal medicine | siRNA | Metabolism | Patients | Fatty acids | Pathology | MicroRNAs | Kidney cancer | Cell lines | Proteomics | Glycolysis | VHL protein | Regulatory proteins | Clear cell-type renal cell carcinoma | Cancer | Apoptosis | Kidney transplantation | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2013, Volume 19, Issue 22, pp. 6173 - 6182
Journal Article
Cancer Discovery, ISSN 2159-8274, 03/2013, Volume 3, Issue 3, pp. 309 - 323
Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to... 
ANAPLASTIC LYMPHOMA KINASE | CELL LUNG-CANCER | DRUG-SENSITIVITY | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | THERAPEUTIC TARGET | N-MYC | C-MYC | ALK KINASE | ACUTE MYELOID-LEUKEMIA | ACTIVATING MUTATIONS | Oncogene Proteins - genetics | RNA, Small Interfering - genetics | Apoptosis - drug effects | Humans | Transcription Factors - deficiency | Apoptosis - genetics | Molecular Targeted Therapy | Transfection | Nuclear Proteins - deficiency | Cell Cycle Checkpoints - genetics | Female | N-Myc Proto-Oncogene Protein | Cell Growth Processes - genetics | Nuclear Proteins - genetics | Child | Neuroblastoma - pathology | Protein Structure, Tertiary | Promoter Regions, Genetic | Neuroblastoma - genetics | Oncogene Proteins - metabolism | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Down-Regulation - drug effects | Azepines - pharmacology | Transcription Factors - metabolism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Gene Amplification | Cell Cycle Checkpoints - drug effects | Neuroblastoma - drug therapy | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Mice | Neuroblastoma - metabolism | Proto-Oncogene Proteins c-myc - genetics | RNA, Small Interfering - administration & dosage | Index Medicus | neuroblastoma | BET bromodomain inhibitor | MYCN | JQ1 | BRD4
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 16, pp. 1629 - 1630
In this issue of Blood, 2 companion papers by Guillerey et al' and Minnie et ale investigate mechanisms underlying immune effector dysfunction in myeloma and... 
MULTIPLE-MYELOMA | TARGETS | HEMATOLOGY | CANCER | Index Medicus | Abridged Index Medicus
Journal Article
Immunity, ISSN 1074-7613, 04/2018, Volume 48, Issue 4, pp. 626 - 628
Immune checkpoint therapy can induce durable remissions, but many tumors demonstrate resistance. In a recent issue of , and identify stromal TGF-β signaling as... 
IMMUNOLOGY | BLOCKADE | CANCER | TUMOR MICROENVIRONMENT | Animals | T-Lymphocytes | Immunotherapy | Mice | Neoplasms | Transforming Growth Factor beta | Disease Models, Animal | Immunoglobulins | Animal models | Colorectal cancer | Clinical trials | Metastasis | Signal transduction | Genotype & phenotype | Carcinogens | Immune checkpoint | Lymphocytes | Response rates | Fibroblasts | Biomarkers | Mutation | Inhibition | Tumors | Apoptosis | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, pp. e57523 - e57523
Sarcomas are rare and heterogeneous mesenchymal tumors affecting both pediatric and adult populations with more than 70 recognized histologies. Doxorubicin and... 
CELL LUNG-CANCER | TRANSFORMATION | IMMUNOCYTOCHEMISTRY | DNA-DAMAGING AGENTS | RETINOIC ACID | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | KINASE | DIFFERENTIATION | CHECKPOINT ABROGATION | P53 | Antimetabolites, Antineoplastic - agonists | Osteosarcoma - drug therapy | Neoplasm Transplantation | Femoral Neoplasms - drug therapy | Pyrazoles - agonists | Pyrimidines - agonists | Femoral Neoplasms - pathology | Humans | Middle Aged | Child, Preschool | Deoxycytidine - pharmacology | Male | Transplantation, Heterologous | Deoxycytidine - agonists | Cell Cycle Proteins - antagonists & inhibitors | Cell Death | Adult | Antimetabolites, Antineoplastic - pharmacology | Female | Cell Differentiation | Child | Pyrazoles - pharmacology | Pyrimidines - pharmacology | Mice, SCID | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Nuclear Proteins - antagonists & inhibitors | Adolescent | Cell Line, Tumor | Mice | Deoxycytidine - analogs & derivatives | Osteosarcoma - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors | Sarcoma | Gemcitabine | Cell death | Metastasis | Drug therapy, Combination | Tumor proteins | Drug therapy | Cdc2 protein | Phosphorylation | Carcinoma | Mesenchyme | Toxicity | Mitosis | p53 Protein | Leukemia | DNA damage | Cytotoxicity | Kinases | Cancer therapies | Doxorubicin | Metastases | Biomedical materials | Osteosarcoma | Xenografts | Cell cycle | Biocompatibility | Inhibition | Drug dosages | Deoxyribonucleic acid--DNA | Explants | Ifosfamide | Mortality | Pharmacology | Tumor cell lines | Chemical compounds | Chemotherapy | Magnetic resonance imaging | Cell lines | Mutation | Tumors | Apoptosis | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
CELL CYCLE, ISSN 1538-4101, 05/2014, Volume 13, Issue 9, pp. 1400 - 1412
Entry and progression through mitosis has traditionally been linked directly to the activity of cyclin-dependent kinase 1 (Cdk1). In this study we utilized low... 
CANCER-CELLS | ACTIVATION | ENTRY | PP2A | SPINDLE ASSEMBLY CHECKPOINT | PROTEIN PHOSPHATASE 2A | GREATWALL KINASE | mitosis | CELL BIOLOGY | CYTOKINESIS | SAC | Cdk1 | cyclin B1 | CELL-CYCLE | RO3306 | EXIT
Journal Article
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7314, pp. 474 - 478
The initiation of eukaryotic DNA replication is regulated by three protein kinase classes: cyclin-dependent kinases (CDK), Dbf4-dependent kinase (DDK) and the... 
ORIGINS | ACTIVATION | BUDDING YEAST | PATHWAY | MULTIDISCIPLINARY SCIENCES | STRESS | SACCHAROMYCES-CEREVISIAE | S-PHASE CHECKPOINT |